WADA Prohibited is a recurring topic in our peptide coverage. This hub collects every article tagged WADA Prohibited, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
A clinical monograph on PEG-MGF — the pegylated Mechano Growth Factor E-peptide marketed for muscle repair and recovery. Preclinical-only evidence, no human trials, and a restricted 2026 legal status.
A clinical monograph on P21 (P021, Ac-DGGLAG-NH2) — a small-molecule CNTF mimetic marketed as a nootropic peptide. Reproducible rodent neurogenesis and anti-tau data, but zero human trials and an unapproved-research-chemical status.
A clinical monograph on N-Acetyl Semax Amidate — the terminally-stabilized analog of the Russian nootropic Semax. No human or animal data on the modified molecule, an unproven potency story, and an unsettled 2026 legal status.
A clinical monograph on N-Acetyl Selank Amidate — a twice-stabilized analog of the Russian anxiolytic peptide Selank. No dedicated human or animal study exists; every claim is extrapolated, placing the analog itself at evidence grade D.
A clinical monograph on the mitochondrial-derived peptide (MDP) axis — MOTS-c, humanin and the small humanin-like peptides (SHLP). One coherent mechanism, three very different maturity tiers, and zero approved human therapies.
A clinical monograph on MOTS-c — the 16-amino-acid mitochondrial-derived peptide marketed as an 'exercise mimetic' and metabolic regulator. Striking rodent data, no completed human efficacy trial, and an unsettled 2026 legal status.
A clinical monograph on MGF (IGF-1Ec) — the mechanosensitive IGF-1 splice variant marketed for muscle repair and satellite-cell activation. Compelling rodent mechanism, contested preclinical data, zero human trials, and an unsettled 2026 legal and anti-doping status.
A clinical monograph on MK-677 (ibutamoren) — the oral, non-peptide ghrelin-receptor agonist that reliably raises GH and IGF-1, yet failed its clinical disease endpoints and carries a congestive-heart-failure safety signal.
A clinical monograph on Melanotan II (MT-II) — the non-selective melanocortin agonist sold illegally for tanning. Thin 1990s human data, a high-risk safety profile, and an unapproved 2026 legal status.
A clinical monograph on Melanotan I — INN afamelanotide, marketed as SCENESSE — the only FDA-approved melanocortin agonist, with Grade-A EPP photoprotection data and a separate unapproved gray-market tanning identity.
A clinical monograph on larazotide acetate (AT-1001) — the gut tight-junction regulator developed for celiac disease. Real Phase 2 symptom data, a failed Phase 3, and an unapproved 2026 legal status.
A clinical monograph on KPV — the anti-inflammatory tripeptide fragment of alpha-MSH. Deep rodent and cell-culture data for gut and skin inflammation, zero human trials, and an unsettled 2026 legal status.
A clinical monograph on Kisspeptin-10 (KP-10), the KISS1R/GPR54 agonist that drives the reproductive axis. Robust human physiology data, no Grade-A outcome RCT, and a 2026 legal status that is not-approved, non-compoundable and banned in sport.
A clinical monograph on ipamorelin — the selective growth-hormone secretagogue famous for the CJC-1295 stack. One human PD study, one failed RCT, and an unsettled 2026 legal status.
A clinical monograph on the tesamorelin + ipamorelin stack — a GHRH-analog plus ghrelin-receptor agonist combination marketed for body composition. Sound mechanism, Grade-A component data, but zero RCTs of the combination itself.
A clinical monograph on insulin — the prototype FDA-approved therapeutic peptide. Grade-A human evidence in diabetes, a tyrosine-kinase mechanism, and a stark warning on lethal non-medical 'anabolic' misuse.
A clinical monograph on IGF-1 LR3 (Long R3 IGF-1) — the IGFBP-evading, long-acting IGF-1 receptor agonist sold as a lab reagent. Real animal anabolic signal, zero human trials, and serious hypoglycemia and cancer-promotion concerns.
A clinical monograph on des(1-3)IGF-I — the truncated, IGFBP-evading IGF-1 analogue marketed for localized muscle growth. Potent in rodents, unproven in humans, and WADA-banned at all times.
A clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.
WADA Prohibited is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged WADA Prohibited, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.